Table 3.
Overall survival according to age, risk categories, and gene mutations.
| Factor | No. Patients | OS (Months) | 95% CI | p |
|---|---|---|---|---|
| Age | 0.002 | |||
| ≥70 years | 142 | 28.9 | 21.0–37.3 | |
| <70 years | 77 | 51.0 | 37.9–64.1 | |
| Cytogenetic risk | 0.001 | |||
| Low | 110 | 51.0 | 40.7–61.4 | |
| Intermediate | 22 | 30.4 | 23.6–37.2 | |
| High | 24 | 19.4 | 9.1–29.8 | |
| FAB | 0.04 | |||
| MDS | 148 | 40.3 | 32.3–49.3 | |
| MPN | 70 | 21.3 | 14.7–27.8 | |
| WHO | 0.227 | |||
| CMML-0 | 151 | 37.7 | 29.4–45.9 | |
| CMML-1 | 35 | 25.0 | 19.1–30.9 | |
| CMML-2 | 27 | 18.3 | 11.3–25.4 | |
| CPSS | 0.01 | |||
| Low | 57 | 57.2 | 35.4–78.8 | |
| Intermediate-1 | 44 | 34.8 | 10.3–59.3 | |
| Intermediate-2 | 43 | 19.4 | 13.8–25.2 | |
| High | 9 | 13.7 | 5.6–21.8 | |
| Dichotomized CPSS | 0.01 | |||
| Low | 101 | 51.6 | 39.9–63.2 | |
| High | 52 | 19.1 | 13.3–24.9 | |
| CPSS-Mol | 0.09 | |||
| Low | 17 | 85.1 | 37.6–132.7 | |
| Intermediate-1 | 12 | 64.3 | 20.3–108.3 | |
| Intermediate-2 | 17 | 46.8 | 12.8–80.8 | |
| High | 14 | 19.1 | 6.7–31.5 | |
| Dichotomized CPSS-Mol | 0.03 | |||
| Low | 29 | 67.3 | 49.6–85.1 | |
| High | 31 | 28.7 | 17.2–40.0 | |
| No. gene mutations | 0.006 | |||
| <2 mutations | 16 | 85.2 | 51.3–119.0 | |
| ≥2 mutations | 56 | 25.0 | 17.6–32.5 | |
| RUNX1 mutation | 0.02 | |||
| Detected | 15 | 16.6 | 10.0–23.0 | |
| Not detected | 57 | 51.1 | 21.5–80.8 | |
| Mutations in transcription factors | 0.001 | |||
| ≥1 mutation detected | 25 | 21.3 | 12.0–30.4 | |
| No mutation detected | 41 | 64.3 | 31.8–96.9 | |
| ASXL1/EZH2 co-mutation | 0.001 | |||
| Detected | 3 | 2.5 | 0.3–4.7 | |
| Not detected | 68 | 35.2 | 10.3–60.2 |